Lithuania Country Drug Report 2019

Public expenditure

Understanding the costs of drug-related actions is an important aspect of drug policy. Some of the funds allocated by governments to expenditure on tasks related to drugs are identified as such in the budget (‘labelled’). Often, however, most drug-related expenditure is not identified (‘unlabelled’) and must be estimated using modelling approaches.

The National Programme for the Control and Prevention of Use of Drugs, Tobacco and Alcohol 2018-28 was adopted in 2018. The previous programme, the National Programme on Drug Control and Prevention of Drug Addiction 2010-16, was implemented with the support of action plans that specified, among other things, public expenditure planned.

In 2017, the labelled expenditure announced in the Action Plan on Drugs, Tobacco and Alcohol was EUR 7.8 million (0.02 % of gross national product (GDP)). More than half of this expenditure was intended for supply reduction (61.7 % of the total); 26.8 % was budgeted for demand reduction and 11.1 % for policy coordination.



Lithuania main page

Methodological note: Analysis of trends is based only on those countries providing sufficient data to describe changes over the period specified. The reader should also be aware that monitoring patterns and trends in a hidden and stigmatised behaviour like drug use is both practically and methodologically challenging. For this reason, multiple sources of data are used for the purposes of analysis in this report. Caution is therefore required in interpretation, in particular when countries are compared on any single measure. Detailed information on methodology and caveats and comments on the limitations in the information set available can be found in the EMCDDA Statistical Bulletin.